Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Warner Chilcott plc | dp36042_ex9901.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 5, 2013
Warner Chilcott Public Limited Company
(Exact name of registrant as specified in its charter)
|
Ireland
|
0-53772
|
98-0626948
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
1 Grand Canal Square, Docklands
Dublin 2, Ireland
(Address of principal executive offices, including zip code)
+353 1 897 2000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01.
|
Other Events.
|
On February 5, 2013, Warner Chilcott plc issued a press release announcing that the United States Food and Drug Administration had approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis, which will be marketed as DELZICOL™ (mesalamine) 400 mg delayed-release capsules.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press Release issued February 5, 2013
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WARNER CHILCOTT PUBLIC LIMITED COMPANY
|
|||
| By: |
/s/ Paul Herendeen
|
||
| Name: |
Paul Herendeen
|
||
| Title: |
Executive Vice President and Chief Financial Officer
|
||
Date: February 5, 2013
|
Exhibit
Number
|
Description
|
|
99.1
|
Press Release issued February 5, 2013
|